PE20181354A1 - Mutantes de proteina f de rsv - Google Patents

Mutantes de proteina f de rsv

Info

Publication number
PE20181354A1
PE20181354A1 PE2018001128A PE2018001128A PE20181354A1 PE 20181354 A1 PE20181354 A1 PE 20181354A1 PE 2018001128 A PE2018001128 A PE 2018001128A PE 2018001128 A PE2018001128 A PE 2018001128A PE 20181354 A1 PE20181354 A1 PE 20181354A1
Authority
PE
Peru
Prior art keywords
mutation
combination
electrostatic
protein
mutant
Prior art date
Application number
PE2018001128A
Other languages
English (en)
Inventor
Ye Che
Philip R Dormitzer
Alexey Vyacheslavovich Gribenko
Luke David Handke
Avvari Krishna Prasad
Xiayang Qiu
Mark Edward Ruppen
Xi Song
Kena Anne Swanson
Srinivas Kodali
Xin Xu
KariAnn Sweeney Efferen
Ping Cai
Kristin Rachael Tompkins
Lorna del Pilar Nunez
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20181354A1 publication Critical patent/PE20181354A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a un mutante de proteina F de virus sincicial respiratorio (RSV) de tipo silvestre, cuyo mutante comprende un polipeptido F1 y un polipeptido F2, en donde el mutante comprende al menos una mutacion de aminoacidos de la proteina F de RSV de tipo silvestre, y en donde la mutacion de aminoacidos se selecciona del grupo consistente de una mutacion de enlace disulfuro, una mutacion de carga de cavidad, una mutacion electrostatica, una combinacion de al menos una mutacion de disulfuro disenada y al menos una mutacion de carga de cavidad, una combinacion de al menos una mutacion de disulfuro disenada y al menos una mutacion electrostatica, una combinacion de al menos una mutacion de carga de cavidad y al menos una mutacion electrostatica, y una combinacion de al menos una mutacion de disulfuro disenada, al menos una mutacion de carga de cavidad y al menos una mutacion electrostatica. Tambien se refiere a una vacuna y un metodo. Dicho mutante de proteina reduce la infeccion por RSV
PE2018001128A 2015-12-23 2016-12-09 Mutantes de proteina f de rsv PE20181354A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387270P 2015-12-23 2015-12-23
US201662421184P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
PE20181354A1 true PE20181354A1 (es) 2018-08-22

Family

ID=57590746

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2023001148A PE20240817A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2018001128A PE20181354A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2023001147A PE20232039A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2023001148A PE20240817A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2023001147A PE20232039A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Country Status (18)

Country Link
US (5) US9950058B2 (es)
EP (1) EP3393512A1 (es)
JP (4) JP6817307B2 (es)
KR (3) KR20230035429A (es)
CN (1) CN108738312A (es)
AU (4) AU2016379097C1 (es)
BR (1) BR112018010805A2 (es)
CA (2) CA2952131C (es)
CO (1) CO2018006301A2 (es)
IL (2) IL260203B1 (es)
MX (2) MX2018007622A (es)
PE (3) PE20240817A1 (es)
PH (1) PH12018501355A1 (es)
RU (1) RU2723039C2 (es)
SA (2) SA522433260B1 (es)
SG (2) SG10202001389PA (es)
TW (4) TWI707866B (es)
WO (1) WO2017109629A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
KR20200035115A (ko) 2017-08-07 2020-04-01 칼더 바이오사이언시스 인코포레이티드 입체형태적으로 안정화된 rsv 융합전 f 단백질
WO2019147749A2 (en) * 2018-01-29 2019-08-01 Merck Sharp & Dohme Corp. Stabilized rsv f proteins and uses thereof
KR20200138234A (ko) 2018-02-28 2020-12-09 유니버시티 오브 워싱톤 자기 조립 나노구조 백신
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
KR20210091749A (ko) * 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP4083212A4 (en) 2019-12-23 2024-03-27 Mitsubishi Tanabe Pharma Corporation MUTANT RSV-F PROTEIN AND ITS USE
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN112899214B (zh) * 2020-07-07 2023-08-04 湖南师范大学 废弃鱼鳞在制备各向异性基底中的应用
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685676B (zh) * 2020-12-28 2024-02-13 兰州生物制品研究所有限责任公司 一种重组蛋白及其表达方法、纯化方法及用途
KR20230147156A (ko) * 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN117986382A (zh) * 2022-11-04 2024-05-07 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
CN117487823A (zh) * 2023-09-28 2024-02-02 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
CN117777251B (zh) * 2024-02-27 2024-06-04 普大生物科技(泰州)有限公司 一种rsv纳米颗粒疫苗及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2008154456A2 (en) 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EP4219566A3 (en) * 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
BRPI0915960A2 (pt) 2008-07-18 2019-09-24 Id Biomedical Corp antígenos de polipeptídeos do vírus sincicial respiratório qimérico
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
US9492531B2 (en) * 2009-06-24 2016-11-15 Glaxosmithkline Biologicals Sa Recombinant RSV vaccines
EA201270062A1 (ru) * 2009-06-24 2013-02-28 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Вакцина
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
EP2486053B1 (en) 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
DK2667892T3 (da) 2011-01-26 2019-05-13 Glaxosmithkline Biologicals Sa RSV-vaccineringsprogram
JP2014519819A (ja) * 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
CA2849471A1 (en) 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
BR112014023196B1 (pt) 2012-03-22 2021-09-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
CA2902877A1 (en) * 2013-03-13 2014-10-02 Jeffrey Boyington Prefusion rsv f proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
EP3344290A4 (en) * 2015-08-31 2019-02-27 Technovax, Inc. VACCINE BASED ON VIRUS-LIKE PARTICLES OF HUMAN RESPIRATORY SYNZYTIAL VIRUS (HRSV)
US10496141B2 (en) 2016-03-17 2019-12-03 Qualcomm Incorporated System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture

Also Published As

Publication number Publication date
TW202124414A (zh) 2021-07-01
TWI656130B (zh) 2019-04-11
CN108738312A (zh) 2018-11-02
AU2019210579B2 (en) 2021-01-28
KR20230035429A (ko) 2023-03-13
KR20200090932A (ko) 2020-07-29
US10238732B2 (en) 2019-03-26
IL311990A (en) 2024-06-01
CA2952131C (en) 2023-12-05
TW201920238A (zh) 2019-06-01
AU2023214269A1 (en) 2023-10-12
KR102505354B1 (ko) 2023-03-02
MX2021007070A (es) 2021-08-11
SA518391839B1 (ar) 2023-10-22
TWI838685B (zh) 2024-04-11
RU2018122823A3 (es) 2020-01-23
SG11201804148TA (en) 2018-07-30
US20170182151A1 (en) 2017-06-29
JP2022185022A (ja) 2022-12-13
KR20180081614A (ko) 2018-07-16
PH12018501355A1 (en) 2019-02-18
TWI756828B (zh) 2022-03-01
AU2016379097A1 (en) 2018-06-07
CA3217696A1 (en) 2017-06-23
PE20240817A1 (es) 2024-04-18
CO2018006301A2 (es) 2018-07-10
US20210023200A1 (en) 2021-01-28
TW202216738A (zh) 2022-05-01
PE20232039A1 (es) 2023-12-21
RU2018122823A (ru) 2020-01-23
AU2019210579A1 (en) 2019-08-22
KR102136678B1 (ko) 2020-07-22
RU2723039C2 (ru) 2020-06-08
US20190125861A1 (en) 2019-05-02
MX2018007622A (es) 2018-11-14
SA522433260B1 (ar) 2024-06-24
US20230218738A1 (en) 2023-07-13
US9950058B2 (en) 2018-04-24
IL260203B1 (en) 2024-05-01
AU2016379097B2 (en) 2019-08-22
WO2017109629A1 (en) 2017-06-29
RU2020115606A (ru) 2020-06-29
AU2021202522A1 (en) 2021-05-27
BR112018010805A2 (pt) 2018-11-27
JP2023015335A (ja) 2023-01-31
JP2021061845A (ja) 2021-04-22
SG10202001389PA (en) 2020-04-29
TWI707866B (zh) 2020-10-21
AU2021202522C1 (en) 2023-11-23
CA2952131A1 (en) 2017-06-23
JP6817307B2 (ja) 2021-01-20
TW201726709A (zh) 2017-08-01
RU2020115606A3 (es) 2020-11-23
AU2016379097C1 (en) 2021-04-08
JP2019511998A (ja) 2019-05-09
JP7193522B2 (ja) 2022-12-20
AU2021202522B2 (en) 2023-05-11
US20180177864A1 (en) 2018-06-28
IL260203A (en) 2018-07-31
JP7212198B2 (ja) 2023-01-24
US10821171B2 (en) 2020-11-03
EP3393512A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
PE20181354A1 (es) Mutantes de proteina f de rsv
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
EA201892250A1 (ru) Вакцина против rsv
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
EA201990071A1 (ru) Композиция пептидной вакцины
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
EA201892251A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
EA201892202A1 (ru) Способы лечения холестатических заболеваний
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
AR108920A1 (es) Partículas y composiciones de nicotina
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
PE20181176A1 (es) Composiciones biofarmaceuticas
WO2015107363A3 (en) Mycobacterial antigen composition
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
EA201990998A1 (ru) Фармацевтические составы и способы их получения
NZ774126A (en) Spd-1 variant - fc fusion proteins
BR112017007370A2 (pt) "conjunto separador de pedra para uma colheitadeira"
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.